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Abstract
Retrospective and prospective studies unambiguously show that prophylactic treatment of severe hemophilia A or
B should be started as primary prophylaxis at 1–2 years’ of age and ideally before the first joint bleed. The dose and
dose frequency should be individually tailored depending on the goal of treatment, venous access and the bleeding
phenotype. The circumstances during the first exposures of factor VIII concentrates in hemophilia A may have
an impact on the risk of developing inhibitors. Enhanced half-life products, in particular in hemophilia B, will
facilitate treatment in patients with difficult venous access but also in achieving a higher trough level. Evidence
accumulate that prophylactic treatment is beneficial also in adults and in patients with inhibitors.
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Background
According to a joint statement made by the World
Health Organization (WHO) and the World Federation
of Hemophilia (WFH), initiating prophylactic treatment
at an early age is considered to be the optimal form of
therapy for a child with severe hemophilia [1–3]. How-
ever, at that time no definition was given of ‘prophylactic
therapy’ for hemophilia. According to a suggested defin-
ition from the Scientific and Standardization Committee
(SSC) of the International Society on Thrombosis and
Haemostasis (ISTH) [4], primary prophylaxis is a continu-
ous therapy starting after the first joint bleed and before
the age of 3 years. Alternatively, primary prophylaxis can
be a continuous treatment started before the age of 3 years
in a patient without any previous joint bleed (i.e. initiated
based solely on age). Secondary prophylaxis can either
be continuous long-term treatment started after two or
more joint bleeds, or after the age of 3 years; however,
secondary prophylaxis can also be an intermittent peri-
odic prophylactic treatment.
Prophylactic treatment using various regiments has
been practiced for many decades in Sweden and The
Netherlands and have clearly demonstrated the benefit
of prophylaxis in several retrospective and observational
studies. However, the randomized controlled US study
of Manco-Johnson et al. [5] gave the final proof of the
concept of prophylactic treatment of children. Sixty boys
were randomly assigned to prophylaxis (n = 32) or on-
demand therapy (n = 32). The boys in the prophylactic
group had a median of 1.2 hemorrhages versus 17.1
per year in the on demand group and had, respect-
ively, a mean of 0.6 joint bleeds per year compared to
4.9. However, at the same time they consumed three
times as much factor VIII (FVIII) although there was
a tendency to increased consumption over time in the
on demand group.
In the literature one may find a variety of opinions on
when to start treatment prophylactic treatment, the dose
and dosage interval [6]. Most children in the world do
not have access to prophylactic treatment, the main
obstacles being the cost of FVIII/IX concentrates and, at
least in the youngest age group, venous access.
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Do children with hemophilia B have the bleeding
phenotype as those with hemophilia A and thus the
same need for prophylactic therapy? In a recent paper,
based on the PedNet Registry, Clausen et al. [7] found
no difference in the bleeding phenotype in early age of
severe or moderate hemophilia A and B that could mo-
tivate a different approach to prophylactic treatment in
hemophilia B compared to hemophilia A.
Review
When should prophylactic treatment begin?
The experience from Sweden (Astermark et al. [8]) sug-
gests that prophylaxis should be started early. In that
study, the frequency of joint bleeds and joint scores were
assessed in 121 patients with severe hemophilia and pa-
tients were stratified in and three subgroups: (1) children
who had begun prophylaxis before age 3 years (n = 75),
(2) children between age 3–5 years (n = 31), and (3)
those who had begun between age 6–9 years (n = 15).
The group starting prophylaxis before two years of age
had a significantly higher proportion of children with no
joint damage compared to the other groups, demonstrat-
ing the benefit of starting prophylactic treatment at an
early age.
The objectives of the Canadian ‘Hemophilia Dose Es-
calation Prophylaxis Trial’, was to avoid a central venous
access device and to individualize treatment according
to the observed bleeding phenotype [9]. Children were
initially treated once-weekly with 50 IU/kg and the fre-
quency of injections was escalated in a stepwise fashion
if unacceptable bleeding occurred. Several bleeds during
a 3-month period were accepted before escalating and
despite a rather good outcome on physical examination,
evaluation by magnetic resonance imaging (MRI) of 24
subjects revealed osteochondral changes in 50 % of the
subjects and 9 % of the joints. For the future it will prob-
ably be of clinical significance that soft tissue changes
were detected in, 75 % of ankles (12/16), 19 % of elbows
(6/32) and 12 % of knees (2/17) that had been reported
as “bleed free” [10].
The benefits of prophylactic treatment are usually
evaluated by different joint outcome measurers. The risk
of intracranial hemorrhage (ICH) after the neonatal
period is 20–50 times higher in a person with hemophilia
on demand treatment compared to a non-hemophiliac
[11–14]. This is a fact that should be taken into account
when discussing in particular the dose interval in prophy-
lactic treatment of hemophilia.
Once hemophilic arthropathy has begun it may, at
least in some susceptible individuals, progress despite
adequate therapy [15] and higher doses are needed to
keep the patient bleed free. This is another argument
for primary prophylaxis to be started before the first
joint bleed.
Which dose and dose interval?
The prophylactic regiment used is dependent on the
objective of treatment, the economic resources available
and, in particular in young children, venous access. A
vision for the future of a trough level of 15 % has been
expressed by the World Federation of Hemophilia
(WFH) [16]. The outcome related to start of treatment
and the dose used, was studied in a long-term follow-up
[17] of the prophylactic regimens for patients with severe
hemophilia (FVIII/IX < 1 IU/dL) in The Netherlands
and Sweden, the two countries with the longest clinical
experience of prophylaxis but with slightly different
approach to age at start of treatment and dosing. The
patients were born between 1970 and 1994 and had at
follow up a median age of approximately 25 years. Early
start of treatment and higher doses gave fewer joint
bleeds but small differences were found at this age in
clinical outcome parameters. However, the cost for the
high dose regimen was twice. The life-long outcome,
and thus if the higher costs of a “high-dose” model is
justified, are presently unknown.
Several studies suggest that there is a subgroup of pa-
tients who are more susceptible to synovitis and pro-
gressive arthropathy after a joint bleed. The existence of
subclinical bleeds was suggested several years ago from
Sweden [18, 19], and has been suggested as cause of ad-
vanced joint changes found on MRI in patients reporting
no or very few joint bleeds [5, 20]. The problem is that
we have little knowledge how to define this subgroup
who are most susceptible to developing arthropathy.
Individualized prophylactic regimens
It is obvious that the prophylactic dose and dosage inter-
val should be tailored individually, depending on the
clinical aim of treatment, the bleeding phenotype, the
patient’s daily activities, venous access and cost-efficacy
being the most important factors. The time spent with a
FVIII level below 1 IU/dL in patients with hemophilia A
is associated with both the total number of bleeds and
the number of joint bleeds [21]. Pharmacokinetic (PK)
measurement is a useful tool to guide and monitor treat-
ment. It can also be used to educate patients, for ex-
ample, that a dose escalation on Friday to cover the
whole weekend would require very high doses of FVIII
[22]. Web-based user-friendly instruments have been
developed that will facilitate PK evaluation of changes in
dose and dose interval in the individual patient. This will
be most useful when introducing extended half-life
concentrates [23].
Prophylaxis and inhibitors
Several studies in hemophilia A have shown that pa-
tients, starting the first 20 exposures as prophylactic
treatment, compared to on demand treatment due to a
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bleed, have a decreased risk to develop inhibitors [24–27].
The RODIN study [28], which is a prospective observa-
tional study (n = 574), modified these finding since it did
not show any difference in the rate of inhibitors during
the first 20 exposure days between prophylaxis and
on-demand treatment. However, after the first 20 ex-
posure days, prophylaxis was associated with a HR
(hazard ratio) of 0.68; 95 % CI: 0.47–0.99, i.e. a pro-
tective effect and the inhibitors that developed were
mainly low titer. It may indicate that some patients at
high risk to develop inhibitors (type of mutation, fam-
ily history of inhibitors and other genetic risk factors)
will develop inhibitors despite the mode of treatment
they receive during the first 20 exposure days. How-
ever, in patients with low genetic risk it seems that it
may be possible to reduce the risk of inhibitors by
introducing regular prophylactic treatment.
In addition, one should probably in severe hemophilia A
during the first 20 exposure days, avoid ‘immunological
danger signals’ such as inflammation/infection/vaccin-
ation, intensive treatment with high doses on consecutive
days for example during surgical procedures.
Inhibitors are less frequent in hemophilia B and we do
not know if the risk factors for inhibitors found in
hemophilia A are applicable also to hemophilia B.
Prophylaxis in adults
Opinions vary on the need of prophylactic treatment in
adulthood. The SPINART study [29] is the first prospect-
ive, controlled, randomized study comparing routine
prophylaxis with on-demand treatment in adults with se-
vere hemophilia A. The median number of total bleeding
episodes and total bleeding episodes per year were signifi-
cantly lower with prophylaxis than with on-demand treat-
ment (total: 0 versus 54.5; total per year: 0 versus 27.9;
both P < 0.0001). A Swedish retrospective study on
prophylaxis in adults showed that only 36 % of all patients
experienced a joint bleed in a 3-year period [30]. In com-
parison, patients treated with on-demand therapy are
likely to have 30–35 joint bleeds per year [31].
Prophylaxis and enhanced half-life (EHL) products
Novel longer-acting products are now being introduced
or are in the pipeline from several manufacturers [32].
The half-life is only moderately prolonged in recombin-
ant FVIII (1.5-fold) but significantly prolonged in recom-
binant FIX (2.4-4.8-fold). Three EHL-rFIX products
have completed phase 3 clinical studies [33–35]. Differ-
ent principles have been used to prolong action in these
three concentrates, fusion with albumin respectively
Fc portion of IgG or addition of a PEG (polyethylen-
glycole). The experiences have been good when using
EHL- FIX for prophylaxis with a dosing frequency be-
tween 7 and 14 days.
Fc fusion and PEGylation technologies have also
been used to produce EHL-rFVIII. There are 4 EHL-
FVIII, one Fc-fusion and three pegylated products of
which some licensed in some countries and some are
under development. The pegylated products have used
different strategies concerning the pegylation and also
attach PEGs of different sizes, 60, 40 and 2 × 20 kDa
[36]. One of them uses full-length rFVIII while the
other three are B-domain deleted rFVIII. The half-life
extension of rFVIII products is in the range of
1.4–1.6 fold, considerably shorter than EHL-FIX. Not
much data are published yet on PUPs and we do
not know the frequency of inhibitors that will develop
in PUPs.
In patients with difficult venous access, products
with an enhanced half-life will be useful and improve
compliance. However, the experience we have gained
from the conventional concentrates may not be
applicable to the longer-acting ones without some
considerations. Most patients will, with less frequent
injections and without increasing the consumption of
concentrate, probably spend a longer time under a
certain concentration and have fewer peaks, which
may increase the risk for breakthrough bleeds,
subclinical/micro-bleeds and change our view on
allowance of sports activities. On the other hand,
depending on costs, the availability of the longer-
acting products opens up a scenario that persons with
hemophilia with today’s frequency of injections may
have a trough level equivalent to that of a patient
with mild hemophilia, which would be a paradigm
shift.
Prophylactic treatment of patients with inhibitors
Patients with hemophilia A or B who have developed inhib-
itors may be treated prophylactically with increased doses
of FVIII/IX if the inhibitor titer is very low (max. 1–2 BU).
Bypassing agents, activated prothrombin complex concen-
trates (aPCC; FEIBA® Baxalta) and the recombinant acti-
vated factor VII (rFVIIa; Novo- Seven®, Novo Nordisk),
have been used to treat bleeding episodes in patients with
inhibitors. However, the benefits of prophylaxis with
bypassing agents are not as efficacious as in non-inhibitor
patients, but they have been shown to be effective in three
prospective, randomized trials. Two studies evaluated
aPCC, Pro–FEIBA and PROOF studies [37, 38], with a 60–
72 % reduction of bleeding episodes compared to on-
demand therapy and one evaluated rFVIIa [39] with up to
60 % reduction of bleeding episodes compared to the pre-
prophylactic period. Prophylactic treatment of patients with
inhibitors may be considered in the pre-ITI period, during
ITI or in cases with failed ITI. The problems are the short
half-life of the by-passing agents, the lower efficacy com-
pared to FVIII/IX and the considerable costs which have
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limited its use. A panel of Spanish hematologists has re-
cently made a systematic review of the literature with the
objective to develop consensus based guidelines [40].
Conclusions
Initiating treatment at an early age is the optimal form of
therapy for a child with hemophilia A or B. The dose and
dosage interval of prophylactic treatment are dependent
on the goal of therapy, the available economic resources
and venous access [41]. The number of joint bleeds should
not be the only outcome parameter, the risk of subclinical
micro-bleeds as well as the risk for intracranial bleeds
need to be considered [41]. Pharmacokinetics is a useful
tool to monitor treatment. There is evidence that prophy-
laxis should be extended into adulthood [41].
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